Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 14:00 ET | Source: Circle Cardiovascular Imaging Inc.

Circle CVI Announces FDA Clearance for cvi42 | Plaque for Coronary Artery Disease Evaluation

Circle CVI has received FDA 510(k) clearance for cvi42 | Plaque, its AI-enabled coronary plaque analysis solution.
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical ogłasza przełomowe wyniki badań klinicznych DynamX® Bioadaptor – wskazujące na niemal 50% redukcję częstości występowania nieporządanych incydentów wieńcowych w porównaniu do obecnego standardu leczenia PCI

Wyniki zaprezentowano podczas konferencji Transcatheter Cardiovascular Therapeutics (TCT) 2025 w San Francisco, 27 października 2025 r. DynamX® bioadaptor to pierwsza technologia interwencyjna, która...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical annuncia risultati clinici “late-breaking” significativi per DynamX® Bioadaptor che dimostrano una riduzione vicina al 50% dei tassi di eventi coronarici rispetto all’ attuale standard di cura per l’angioplastica coronarica p

I risultati sono stati presentati durante il congresso annuale sulle terapie cardiovascolari transcatetere (TCT) tenutosi a San Francisco il 27 ottobre 2025. Il DynamX® Bioadaptor è la prima...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP

Les résultats ont été présentés lors de la Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 à San Francisco, le 27 octobre 2025 Le DynamX® Bioadaptor est la première technologie...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical anuncia resultados clínicos recientes y significativos sobre el Bioadaptador DynamX® que demuestran una reducción de casi el 50 % en las tasas de acontecimiento coronarios en comparación con el tratamiento de referencia actua

Los resultados se presentaron en el congreso Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 en San Francisco (EE. UU.) el 27 de octubre de 2025 El Bioadaptador DynamX® es la primera...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical gibt klinische Late-Breaking-Ergebnisse für DynamX® Bioadaptor bekannt, die eine signifikante Reduzierung von koronaren Ereignisraten um nahezu 50 % gegenüber dem aktuellen PCI-Behandlungsstandard zeigen

Die Ergebnisse wurden bei der Transcatheter Cardiovascular Therapeutics (TCT)-Konferenz 2025 in San Francisco am 27. Oktober 2025 vorgestellt. Der DynamX® Bioadaptor ist die erste interventionelle...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to...
October 01, 2025 09:00 ET | Source: Elixir Medical Corporation

Elixir Medical Announces Key Commercial Milestone With LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL)

LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques New clinical study to be presented...
September 22, 2025 16:05 ET | Source: Heartflow, Inc.

Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform

MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received...
August 11, 2025 16:30 ET | Source: Heartflow, Inc.

Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its...